Biosensors International

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Biosensors International (Booth 1456) is featuring clinical data for its BioMatrix Biolimus A9, its new bioresorbable drug-eluting stent platform, which is not yet available in the U.S.

BioMatrix is mounted on a low-profile delivery system enabling access to difficult lesions and vessel physiologies. In combination with its proprietary drug, Biolimus A9, has a bioresorbable polylactic acid polymer coating which is co-released with Biolimus A9, reaching therapeutic concentrations during therapeutic window when cells are proliferating. The Biolimus A9 is eluted from bioabsorbable PLA-coated stent in de novo coronary lesions.